JP2019526578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526578A5 JP2019526578A5 JP2019511962A JP2019511962A JP2019526578A5 JP 2019526578 A5 JP2019526578 A5 JP 2019526578A5 JP 2019511962 A JP2019511962 A JP 2019511962A JP 2019511962 A JP2019511962 A JP 2019511962A JP 2019526578 A5 JP2019526578 A5 JP 2019526578A5
- Authority
- JP
- Japan
- Prior art keywords
- kit
- composition
- nanoparticles
- binder
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 52
- 239000011230 binding agent Substances 0.000 claims description 30
- -1 dosetaxel Chemical compound 0.000 claims description 30
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 25
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 25
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 23
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 23
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 23
- 239000002955 immunomodulating agent Substances 0.000 claims description 15
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 12
- 229960005277 gemcitabine Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 229930012538 Paclitaxel Natural products 0.000 claims description 9
- 229960001592 paclitaxel Drugs 0.000 claims description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 5
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 5
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 5
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 190000008236 carboplatin Chemical compound 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229960002448 dasatinib Drugs 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 229960001904 epirubicin Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- 229960001156 mitoxantrone Drugs 0.000 claims description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 5
- 229950007221 nedaplatin Drugs 0.000 claims description 5
- 190000005734 nedaplatin Chemical compound 0.000 claims description 5
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 5
- 229960000639 pazopanib Drugs 0.000 claims description 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 5
- 229950005566 picoplatin Drugs 0.000 claims description 5
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 5
- 229960005399 satraplatin Drugs 0.000 claims description 5
- 190014017285 satraplatin Chemical compound 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960005167 everolimus Drugs 0.000 claims description 4
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 4
- 229960005079 pemetrexed Drugs 0.000 claims description 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 3
- 229960001573 cabazitaxel Drugs 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 12
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 12
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 4
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 4
- 229960002584 gefitinib Drugs 0.000 claims 4
- 229960000908 idarubicin Drugs 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 229950007213 spartalizumab Drugs 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 229950010773 pidilizumab Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
- 108010000817 Leuprolide Proteins 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229960004891 lapatinib Drugs 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065086A JP2022082806A (ja) | 2016-09-01 | 2022-04-11 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
| JP2024217459A JP2025028161A (ja) | 2016-09-01 | 2024-12-12 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382731P | 2016-09-01 | 2016-09-01 | |
| US62/382,731 | 2016-09-01 | ||
| PCT/US2017/049746 WO2018045239A1 (en) | 2016-09-01 | 2017-08-31 | Carrier-pd-l1 binding agent compositions for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065086A Division JP2022082806A (ja) | 2016-09-01 | 2022-04-11 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526578A JP2019526578A (ja) | 2019-09-19 |
| JP2019526578A5 true JP2019526578A5 (enExample) | 2020-10-01 |
| JP7525999B2 JP7525999B2 (ja) | 2024-07-31 |
Family
ID=60009705
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511962A Active JP7525999B2 (ja) | 2016-09-01 | 2017-08-31 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
| JP2022065086A Withdrawn JP2022082806A (ja) | 2016-09-01 | 2022-04-11 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
| JP2024217459A Pending JP2025028161A (ja) | 2016-09-01 | 2024-12-12 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065086A Withdrawn JP2022082806A (ja) | 2016-09-01 | 2022-04-11 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
| JP2024217459A Pending JP2025028161A (ja) | 2016-09-01 | 2024-12-12 | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11548946B2 (enExample) |
| EP (2) | EP4177271A1 (enExample) |
| JP (3) | JP7525999B2 (enExample) |
| KR (2) | KR20220151022A (enExample) |
| CN (1) | CN109890419A (enExample) |
| AU (1) | AU2017318668A1 (enExample) |
| CA (1) | CA3035378A1 (enExample) |
| ES (1) | ES2937291T3 (enExample) |
| MX (1) | MX2019002474A (enExample) |
| RU (1) | RU2019109211A (enExample) |
| WO (1) | WO2018045239A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200793T1 (hr) | 2011-05-09 | 2020-10-16 | Mayo Foundation For Medical Education And Research | Liječenje raka |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3154586B1 (en) | 2014-06-13 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Treating lymphomas |
| MX2016016617A (es) | 2014-06-16 | 2017-03-23 | Mayo Foundation | Tratamiento de mielomas. |
| US9446148B2 (en) * | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| WO2016197100A1 (en) | 2015-06-04 | 2016-12-08 | Crititech, Inc. | Nozzle assembly and methods for use |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| PT3439635T (pt) | 2016-04-04 | 2021-02-11 | Crititech Inc | Formulações para tratamento de tumores sólidos |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| MX2019002473A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Métodos y composiciones para el direccionamiento de cánceres de células t. |
| KR20220151022A (ko) | 2016-09-01 | 2022-11-11 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| CA3035653A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CA3035655A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| US11531030B2 (en) | 2017-04-21 | 2022-12-20 | Mayo Foundation For Medical Education And Research | Polypeptide-antibody complexes and uses thereof |
| KR20200014279A (ko) | 2017-06-09 | 2020-02-10 | 크리티테크, 인크. | 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료 |
| JP6840869B2 (ja) | 2017-06-14 | 2021-03-10 | クリチテック，インコーポレイテッド | 肺障害の治療方法 |
| CA3076919A1 (en) * | 2017-10-03 | 2019-04-11 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
| US20210023233A1 (en) * | 2018-02-06 | 2021-01-28 | Mayo Foundation For Medical Education And Research | Antibody-peptide complexes and uses thereof |
| CN109512798B (zh) * | 2019-01-15 | 2022-05-13 | 南京从一医药科技有限公司 | 一种用于抗肿瘤免疫治疗的药物组合物纳米体系 |
| CN110623942B (zh) * | 2019-09-30 | 2020-09-22 | 武汉大学 | 一种全反式维甲酸纳米药物制剂、其制备方法及应用 |
| TW202130367A (zh) * | 2020-01-15 | 2021-08-16 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途 |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4350687A (en) | 1980-02-10 | 1982-09-21 | Research Corporation | Platelet derived cell growth factor |
| JPS60146833A (ja) | 1984-01-10 | 1985-08-02 | Green Cross Corp:The | モノクロ−ナル抗体製剤 |
| JPS6178731A (ja) | 1985-05-20 | 1986-04-22 | Green Cross Corp:The | 加熱処理免疫グロブリン製剤 |
| CA1327161C (en) | 1987-09-01 | 1994-02-22 | Mitsugu Kobayashi | Lyophilized pharmaceutical composition of neocarzinostatin derivative |
| SE8801537D0 (sv) | 1988-04-26 | 1988-04-26 | Ellco Food Ab | Cellodlingsmedium samt forfarande for dess framstellning |
| US5252713A (en) | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
| EP0465513A1 (en) | 1989-03-27 | 1992-01-15 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
| US5116944A (en) | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US5216130A (en) | 1990-05-17 | 1993-06-01 | Albany Medical College | Complex for in-vivo target localization |
| US6147204A (en) | 1990-06-11 | 2000-11-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| DE69128350T2 (de) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5260308A (en) | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| DE69722793T2 (de) | 1996-04-26 | 2004-05-19 | Genaera Corp. | Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren |
| GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| US5728541A (en) | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
| US6416967B2 (en) | 1996-07-12 | 2002-07-09 | Precision Therapeutics, Inc. | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue |
| US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| DK1023050T3 (da) | 1997-06-27 | 2013-10-14 | Abraxis Bioscience Llc | Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf |
| US7041301B1 (en) | 1997-11-07 | 2006-05-09 | Mayo Foundation For Medical Education And Research | Interferon immunotherapy |
| US6616925B1 (en) | 1998-04-02 | 2003-09-09 | I.D.M. Immuno-Designed Molecules | Combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| US6180348B1 (en) | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
| US7112409B2 (en) | 1999-01-29 | 2006-09-26 | Center For Molecular Medicine And Immunology | Method of determining cytokine dosage for myelosuppressive state |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| JP2001072589A (ja) | 1999-07-06 | 2001-03-21 | Toagosei Co Ltd | 制癌剤 |
| US6420378B1 (en) | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| DE10132502A1 (de) | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen |
| BR0309254A (pt) | 2002-04-12 | 2005-03-01 | Medarex Inc | Uso de um anticorpo anti-ctla-4 |
| EP1578362A4 (en) | 2002-07-09 | 2008-11-05 | Point Therapeutics Inc | COMBINATION THERAPY WITH A BOROPROLINE COMPOUND |
| JP4596916B2 (ja) | 2002-09-05 | 2010-12-15 | メディミューン，エルエルシー | Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法 |
| ES2602145T3 (es) | 2002-09-06 | 2017-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| ATE459364T1 (de) | 2003-10-22 | 2010-03-15 | Univ Johns Hopkins | Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren |
| DK1763356T3 (da) | 2004-04-22 | 2008-10-13 | Lilly Co Eli | Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer |
| WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| EP1812864A2 (en) | 2004-10-07 | 2007-08-01 | Emory University | Multifunctional nanoparticles conjugates and their use |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN103285395A (zh) | 2005-02-18 | 2013-09-11 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| JP5185813B2 (ja) | 2005-04-26 | 2013-04-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癌免疫治療のための組成物および方法 |
| US10183076B2 (en) | 2005-05-16 | 2019-01-22 | Resdevco Research And Development Co. L | Topical compositions for treatment of irritation of mucous membranes |
| LT3311805T (lt) | 2005-08-31 | 2020-04-27 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| US7776832B2 (en) | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| NZ576122A (en) | 2006-09-26 | 2012-09-28 | Genmab As | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| US20100173794A1 (en) | 2006-10-17 | 2010-07-08 | Koninklijke Philips Electronics N.V. | Device for amplification and detection of nucleic acids |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20100124583A1 (en) | 2008-04-30 | 2010-05-20 | Xyleco, Inc. | Processing biomass |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| CA2668836A1 (en) | 2006-11-07 | 2008-05-15 | Dow Agrosciences Llc | Sprayable, controlled-release, male annihilation technique (mat) formulation and insect control method |
| WO2008076278A2 (en) | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of cancer treatment with igf1r inhibitors |
| SI2117520T1 (sl) | 2006-12-14 | 2019-01-31 | Abraxis Bioscience, Llc | Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan |
| CA3201293A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100047234A1 (en) | 2007-03-14 | 2010-02-25 | Markovic Svetomir N | Treating skin cancer |
| US20110014117A1 (en) | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| WO2009043159A1 (en) | 2007-10-01 | 2009-04-09 | The Hospital For Sick Children | Neural tumor stem cells and methods of use thereof |
| RU2010120674A (ru) | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| CN101918030B (zh) | 2007-11-09 | 2015-10-14 | 派瑞格恩医药公司 | 抗vegf抗体的组合物和方法 |
| DE102008013565B4 (de) | 2008-03-11 | 2025-12-04 | A. Kayser Automotive Systems Gmbh | Einsteckkupplung |
| WO2010003057A2 (en) | 2008-07-03 | 2010-01-07 | Mayo Foundation For Medical Education And Research | Treating cancer |
| RU2505315C2 (ru) | 2008-07-30 | 2014-01-27 | Нитто Денко Корпорейшн | Носители лекарственных средств |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| EP2321408A4 (en) | 2008-08-04 | 2013-04-17 | Allocure Inc | MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE |
| US8753604B2 (en) | 2008-12-23 | 2014-06-17 | Sanford-Burnham Medical Research Institute | Methods and compositions for synaphically-targeted treatment for cancer |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| EP2416763A4 (en) | 2009-04-06 | 2015-05-06 | Mayo Foundation | PROCESS AND MATERIALS FOR THE RELEASE OF MOLECULES |
| CN102458112A (zh) | 2009-04-10 | 2012-05-16 | 阿布拉科斯生物科学有限公司 | 纳米颗粒制剂及其用途 |
| US8571805B2 (en) | 2009-04-10 | 2013-10-29 | Pharmaco-Kinesis Corporation | Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| CN102458471A (zh) | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2496606A2 (en) | 2009-11-05 | 2012-09-12 | The UAB Research Foundation | Treating basal-like genotype cancers |
| CA2780773A1 (en) | 2009-11-13 | 2011-05-19 | Merck Patent Gmbh | Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents |
| EP3056201A1 (en) | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| EP2625525A4 (en) | 2010-10-08 | 2014-04-02 | Abraxis Bioscience Llc | SPARC MICRO ENVIRONMENT SIGNATURE, PLASMA SPARC AND LDH AS PROGNOSTIC BIOMARKERS IN THE TREATMENT OF CANCER |
| US20130281377A1 (en) | 2010-12-23 | 2013-10-24 | Mayo Foundation For Medical Education And Research | Treating multiple myeloma |
| US20120283290A1 (en) | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| HRP20200793T1 (hr) | 2011-05-09 | 2020-10-16 | Mayo Foundation For Medical Education And Research | Liječenje raka |
| US20130028895A1 (en) | 2011-07-27 | 2013-01-31 | Gerald Wulf | Exosome inhibiting agents and uses thereof |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2013071058A1 (en) | 2011-11-09 | 2013-05-16 | The Uab Research Foundation | Her3 antibodies and uses thereof |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| JP6117921B2 (ja) | 2012-07-12 | 2017-04-19 | ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド | 細胞毒性剤と細胞結合受容体との共役体 |
| ES2871349T3 (es) | 2012-09-04 | 2021-10-28 | Inven2 As | Expansión selectiva y controlada de células NK educadas |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| NZ630239A (en) * | 2013-02-11 | 2017-08-25 | Abraxis Bioscience Llc | Methods of treating melanoma |
| EP4285928A3 (en) | 2013-09-27 | 2024-03-13 | F. Hoffmann-La Roche AG | Anti-pdl1 antibody formulations |
| JP6841656B2 (ja) | 2013-12-17 | 2021-03-10 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| EP3154586B1 (en) | 2014-06-13 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Treating lymphomas |
| MX2016016617A (es) | 2014-06-16 | 2017-03-23 | Mayo Foundation | Tratamiento de mielomas. |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| KR102008859B1 (ko) * | 2014-10-06 | 2019-08-08 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 담체-항체 조성물 및 그의 제조 및 사용 방법 |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| AU2015355137A1 (en) * | 2014-12-02 | 2017-06-08 | Celgene Corporation | Combination therapies |
| WO2017176265A1 (en) | 2016-04-06 | 2017-10-12 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| AU2016308337B2 (en) | 2015-08-18 | 2019-02-28 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON |
| CA3010718A1 (en) | 2016-01-08 | 2017-07-13 | Tti (Macao Commercial Offshore) Limited | Carburetor with maintenance port |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| RU2019105550A (ru) | 2016-08-05 | 2020-09-07 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования |
| MX2019002473A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Métodos y composiciones para el direccionamiento de cánceres de células t. |
| KR20220151022A (ko) | 2016-09-01 | 2022-11-11 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| CA3035655A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| CA3035653A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2018079702A1 (ja) | 2016-10-28 | 2018-05-03 | 株式会社Ｎｒｌファーマ | ラクトフェリン／アルブミン融合タンパク質及びその製造方法 |
-
2017
- 2017-08-31 KR KR1020227037674A patent/KR20220151022A/ko not_active Withdrawn
- 2017-08-31 WO PCT/US2017/049746 patent/WO2018045239A1/en not_active Ceased
- 2017-08-31 RU RU2019109211A patent/RU2019109211A/ru not_active Application Discontinuation
- 2017-08-31 US US16/330,030 patent/US11548946B2/en active Active
- 2017-08-31 CN CN201780067542.2A patent/CN109890419A/zh active Pending
- 2017-08-31 MX MX2019002474A patent/MX2019002474A/es unknown
- 2017-08-31 EP EP22206923.9A patent/EP4177271A1/en active Pending
- 2017-08-31 JP JP2019511962A patent/JP7525999B2/ja active Active
- 2017-08-31 CA CA3035378A patent/CA3035378A1/en active Pending
- 2017-08-31 AU AU2017318668A patent/AU2017318668A1/en not_active Withdrawn
- 2017-08-31 EP EP17778387.5A patent/EP3506942B1/en active Active
- 2017-08-31 KR KR1020197009302A patent/KR102462041B1/ko active Active
- 2017-08-31 ES ES17778387T patent/ES2937291T3/es active Active
-
2022
- 2022-04-11 JP JP2022065086A patent/JP2022082806A/ja not_active Withdrawn
- 2022-11-18 US US18/057,165 patent/US20230159640A1/en not_active Abandoned
-
2024
- 2024-12-12 JP JP2024217459A patent/JP2025028161A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526578A5 (enExample) | ||
| RU2019109211A (ru) | Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака | |
| JP2024042089A5 (enExample) | ||
| JP2019526579A5 (enExample) | ||
| RU2019110070A (ru) | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения | |
| JP2019529388A5 (enExample) | ||
| KR102486057B1 (ko) | Ｐｄ－ｌ１ 발현 암의 치료 방법 | |
| US10493150B2 (en) | Nanoparticle complexes of paclitaxel, alemtuzumab, and albumin | |
| JP2021169479A5 (enExample) | ||
| US20200237907A1 (en) | Methods of Treating Cancer Using Compositions of Antibodies and Carrier Proteins with Antibody Pretreatment | |
| SI2530091T1 (en) | PROTITELO ANTI-DLL3 | |
| JP2018501218A5 (enExample) | ||
| JP2013520442A5 (enExample) | ||
| RU2019109209A (ru) | Способ и композиции для направленного на мишень воздействия при лечении т-клеточных видов рака | |
| JP2018516966A5 (enExample) | ||
| JP2019524701A5 (enExample) | ||
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| RU2015119802A (ru) | Комбинированная терапия рака | |
| JP2018525413A5 (enExample) | ||
| CHAABOUNI et al. | Exploring the Efficacy of Pembrolizumab in combination with carboplatin and weekly paclitaxel for frail patients with advanced non-small cell lung cancer: A Key Investigative Study | |
| AR102307A1 (es) | Composiciones de proteínas portadoras - anticuerpos y métodos para su elaboración y uso |